Ophthalmology · New York, NY
NPI
1679583553
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
5
Medicare group memberships
Hospitals
0
Hospital affiliations
4966 Broadway, Suite #1
New York, NY, 10034
Phone (212) 304-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$1,713
37 services
Medicare patients, 2024
13
Average age 75
Drug cost, 2024
$113K
437 prescriptions
Company payments, 2023
$275
From 3 companies
Medicare prescription drug claims, 2024
In 2024, the drug Elliott M Feinman prescribed most often to Medicare patients was Restasis (Cyclosporine), with 97 prescriptions and refills. In total Elliott M Feinman wrote 437 Medicare prescriptions that cost $113K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-08-16.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Restasis Cyclosporine | 97 | 97 | 29 | $61K |
| Latanoprost Generic | 81 | 106 | 31 | $613 |
| Azelastine Hcl Generic | 77 | 77 | 18 | $821 |
| Bepotastine Besilate Generic | 35 | 53 | 15 | $6,831 |
| Cyclosporine Generic | 25 | 31 | Under 11 | $7,448 |
| Bepreve Bepotastine Besilate | 23 | 34 | Under 11 | $11K |
| Xiidra Lifitegrast | 14 | 14 | Under 11 | $9,642 |
| Zerviate Cetirizine Hcl | 14 | 14 | Under 11 | $2,976 |
| Timolol Maleate Generic | 11 | 23 | Under 11 | $96.31 |
Brand drugs: 257 claims; generic drugs: 180 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Elliott M Feinman $275 ($275 in general payments such as food, travel and fees) from 3 companies. The largest payer was Horizon Therapeutics plc with $124.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.